Skip to Main Content

It’s a holiday week. Things are slow. But we’re still keeping tabs on all things pharma and biotech. Here’s what we’re looking out for this week:

Bad news

If the goal is to bury bad news, this week is the time to do it. Whether it’s a bankruptcy, layoffs, or a decision to give up on an experimental drug, companies have plenty of incentive to get that press release out of the way while hardly anyone’s paying attention. (Don’t worry. We’ll be watching.)


Verdicts from the FDA

Don’t be surprised to see the FDA do a bit of end-of-year housecleaning this week in the form of early approvals or denials for drugs or devices. Keep an eye out for a surprise, like Clovis Oncology’s newly approved ovarian cancer therapy, which won approval last week — two months earlier than scheduled.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!